Peptide Insider

MariTide Side Effects: What the Trials Actually Measured

MariTide side effects — what the trials actually measured

Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn

Evidence-first peptide coverage — every claim on this page is linked to its primary source and reviewed against our editorial policy

Citations verified against PubMed · Published: 2026-09-04 · Last updated: 2026-09-07

MariTide side effects come from a single, unusually well-designed source: a 592-person, 52-week phase 2 trial in the New England Journal of Medicine, placebo-controlled in two cohorts, with arms that started at the full dose randomized against arms that climbed to it. The short answer: gastrointestinal effects were common, less frequent when the dose was escalated or started lower, and no unexpected safety signal emerged. What the published abstract does not give is a nausea percentage, and neither will we. This page covers what was measured, what monthly dosing changes about side effects, and why a “MariTide” vial from a peptide storefront is harder to verify than anything else in this family.

Quick Answer: The Most Common MariTide Side Effects

Gastrointestinal adverse events. The phase 2 abstract’s exact words: “Gastrointestinal adverse events were common with maridebart cafraglutide, although less frequent with dose escalation and a lower starting dose. No unexpected safety signals emerged.” The abstract reports no per-event rates — no nausea, vomiting, or diarrhea percentages, no placebo-arm rate — so any specific figure quoted for MariTide side effects did not come from it. The tolerability finding that is reported is structural: escalating to 420 mg over 4 or 12 weeks produced fewer GI events than starting there. Self-reported experiences from clinical-trial participants on Reddit are summarized further down; they are anecdotes, not data.

★The Documented Experience of 592 Trial Participants

The most complete “user experience” of MariTide that exists belongs to the 592 people who took it under observation — 465 with obesity, 127 with obesity and type 2 diabetes — across 11 groups for 52 weeks. The typical arc: a subcutaneous injection every 4 weeks (every 8 in one arm), gastrointestinal symptoms that were common and fewer when the dose was escalated, and weight down 12.3% to 16.2% in the obesity cohort against 2.5% on placebo.

How tolerable did participants find it? The investigators’ verdict: GI events were “less frequent with dose escalation and a lower starting dose” and “no unexpected safety signals emerged” — a design finding rather than a rate, and the honest limit of what the abstract lets anyone say about how it felt.

What that experience came with: screening, monitoring, pharmaceutical-grade product from Amgen, and clinician-managed dosing — none of which ships with a research vial.

Compiled from the published trial (PMID 40549887) — not from testimonials. When we publish an individual account here, it will be a real person, named with permission.

Research peptide vial

Looking for Lab-Tested Peptides?

Our top-rated vendor publishes batch COAs and third-party testing on every compound — get up to 30% off your first order.

Shop Amino Club →

Affiliate link — it doesn’t change what we report. All compounds sold strictly for non-human research use. Read our full Amino Club review.

In This Guide

What Is MariTide?

MariTide is Amgen’s maridebart cafraglutide, formerly AMG 133: a long-acting peptide-antibody conjugate that combines GLP-1 receptor agonism with GIP receptor antagonism, intended for the treatment of obesity (PMID 40549887). Structurally it is not a peptide as this site uses the word — it is a GLP-1 peptide attached to an IgG antibody that blocks the GIP receptor (PMID 41941715). In its 52-week phase 2, the obesity cohort lost 12.3% to 16.2% of body weight versus 2.5% on placebo (PMID 40549887). It is investigational — in phase 3, not approved anywhere — so anything sold under the name outside a trial is research-market material.

How It Works — and Why It Blocks GIP Instead of Activating It

The GLP-1 half is familiar: slower gastric emptying, quieter appetite, and the gastrointestinal side effects that come with both. The GIP half runs against the grain of its competitors. Tirzepatide and retatrutide activate the GIP receptor; MariTide blocks it with an anti-GIPR antibody (PMID 41941715). Both directions produce weight loss, a paradox the abstracts here don’t attempt to resolve. Amgen built the molecule by conjugating synthetic GLP-1 peptides to IgG-based anti-GIPR antibodies, yielding “markedly prolonged systemic exposure of the structurally intact GLP-1 peptide” — in obese mice and monkeys, once-weekly dosing produced sustained weight loss, and the optimized candidate emerged with “a profile that may support monthly dosing” (PMID 41941715).

KEY TAKEAWAY

MariTide’s side-effect profile is a GLP-1 profile on an antibody’s schedule. The GI events are the GLP-1 half at work; the monthly interval is the antibody half — and the interval, not the mechanism, is what makes MariTide’s tolerability questions different from every weekly compound on this site.

The Trial Numbers That Matter

One dataset carries this page: a double-blind, randomized, placebo-controlled, dose-ranging phase 2 — 592 participants across 11 groups in two cohorts, primary endpoint percent change in body weight at week 52 (PMID 40549887). The obesity cohort (465 participants) was randomized 3:3:3:2:2:2:3 to 140, 280, or 420 mg every 4 weeks without escalation; 420 mg every 8 weeks; 420 mg every 4 weeks after a 4-week or a 12-week escalation; or placebo. Weight change ranged from -12.3% to -16.2% with MariTide versus -2.5% on placebo. The obesity-diabetes cohort (127 participants) was randomized 1:1:1:1 to 140, 280, or 420 mg every 4 weeks without escalation, or placebo; weight change ranged from -8.4% to -12.3% versus -1.7%, and glycated hemoglobin fell 1.2 to 1.6 percentage points versus a 0.1-point rise on placebo. The J Med Chem discovery paper (PMID 41941715) supplies the mechanism; a Nature Reviews Endocrinology highlight on the phase 1 (PMID 38388678) carries no abstract, and we quote nothing from it.

Gastrointestinal Side Effects: What Was Actually Reported

The abstract’s safety reporting is two sentences long; we reproduce it rather than decorate it: “Gastrointestinal adverse events were common with maridebart cafraglutide, although less frequent with dose escalation and a lower starting dose. No unexpected safety signals emerged.” (PMID 40549887). That is a qualitative finding with a structural comparison inside it, not a rate table. There is no nausea, vomiting, or placebo GI rate in the abstract; we won’t launder a number we haven’t seen into “the trial found.” What the abstract does establish is direction: GI events tracked how the dose was reached, not only how high it went.

For scale, the weekly compounds in this cluster with published per-arm rates — survodutide, retatrutide, mazdutide — all report gastrointestinal events as the dominant category, and MariTide’s abstract places it in the same family. Whether monthly dosing makes those events more or less frequent than a weekly GLP-1’s, the abstract doesn’t say.

PERSONAL OBSERVATION — PI EDITORIAL

Reading this abstract next to the weekly-compound abstracts we’ve covered, what struck us was how differently the safety sentence is built. Survodutide’s abstract gives you rates by arm; MariTide’s gives you a comparison between arms. That’s not evasion — the design was several roads to 420 mg — but it means the MariTide side-effect “rates” circulating online are either from the full paper’s tables or invented, and in the listings we’ve reviewed, nobody says which.

Dose Escalation vs None: The Tolerability Finding Built Into the Design

This is MariTide’s distinctive contribution to the side-effect literature, engineered into the randomization. In the obesity cohort, participants reached 420 mg every 4 weeks by three routes: starting there with no escalation, escalating over 4 weeks, or escalating over 12 weeks (PMID 40549887). Same destination, different roads. The abstract’s conclusion — GI events “less frequent with dose escalation and a lower starting dose” — is the cleanest randomized evidence in this family that how you arrive at a dose changes tolerability, independent of the dose itself. Weekly GLP-1 trials assume this; MariTide’s tested it against a no-escalation control. What the abstract doesn’t give is magnitude — how much less frequent, or whether 4 weeks bought most of what 12 did — so we report direction and nothing sharper. The obesity-diabetes cohort ran all three doses without escalation and contributes nothing here.

Injection-Site Reactions

The abstract does not report injection-site reactions; their absence from its two safety sentences means only that they weren’t the headline (PMID 40549887). MariTide is a subcutaneous injection every 4 weeks — every 8 in one arm. The trial product was an antibody conjugate, not a lyophilized peptide powder, so the reconstitution notes below apply to research-market objects sold under the name, not to anything trial participants received.

PRACTICAL NOTES — STANDARD SUBCUTANEOUS HANDLING

  • Reconstituted solutions brought to room temperature before use are standard practice in clinical settings
  • Site rotation (abdomen, thigh, upper arm) is how trial protocols manage repeated injections, monthly or weekly
  • Sterile technique — clean site, single-use needles — is non-negotiable in any protocol, trial or lab
  • Our bacteriostatic water guide covers reconstitution handling in detail

Beyond the Gut: What Else the Trial Recorded

“No unexpected safety signals emerged” is the abstract’s entire statement on everything that isn’t gastrointestinal (PMID 40549887). Read it precisely: it does not say no serious adverse events or deaths occurred — it says nothing outside the expected GLP-1-class pattern turned up. The abstract reports no serious-adverse-event rate, no discontinuation rate, and no cardiovascular, hepatic, or psychiatric findings, so this page reports none. The one non-GI measurement it gives is favorable: in the obesity-diabetes cohort, glycated hemoglobin fell 1.2 to 1.6 percentage points with MariTide against a 0.1-point rise on placebo. For an antibody-based biologic, immunogenicity questions are absent from the abstract too, and we won’t speculate.

What Users Report: Self-Reported Effects From Reddit

The phase 2 trial above found gastrointestinal events common and fewer with dose escalation, but published no per-event rates; descriptions of how MariTide feels exist only online. And there is no gray-market MariTide: every poster describing it says they are in an Amgen trial, so these are trial-participant anecdotes whose confounder is blinding, not product identity. None can know whether they got active drug, placebo, or which dose. We searched Reddit on September 5, 2026, found 39 relevant posts from 2024 to 2026, and read the comment threads of six, across r/MariTide, r/glp1 and r/Mounjaro. Everything below is paraphrased and linked, uses no usernames, and describes products nobody verified; here, nobody verified the enrollment or the arm either.

Nausea, sulfur burps and, for a few, vomiting dominate the early doses. At least nine distinct posters describe nausea or vomiting. A poster in the diabetes cohort had major nausea and vomiting through the first few months, managed with prescribed Zofran (r/MariTide). A third-injection poster there reported awful sulfur burps and two bouts of strong vomiting; another, vomiting after every meal for four days after the second shot, considered leaving the trial. Burping appears in at least five accounts, one with alternating constipation and diarrhea (thread). A poster fifty-two weeks in at a German site reported only slight nausea on the first two doses (r/MariTide).

Fatigue is the complaint that outlasts the nausea. At least eight posters describe tiredness or new napping. One still could not shake it on her third shot, while noting an unusually bad period in the first fortnight (r/MariTide). A poster four months in had fatigue and nausea for two to three days after each monthly dose, gone a year later (thread). Headache appears in three accounts, two blamed partly on heat or too little water; one had injection-site pain, only on the fourth shot.

Because the trials are blinded, feeling nothing is the most contested report. At least four posters describe no side effects, and most read it as placebo. One had zero symptoms across three loading doses yet lost weight, was told by the site that many phase 2 participants felt nothing until the higher doses, and at forty-eight weeks was still unsure they ever got active drug (r/MariTide). A poster on the highest dose reported no side effects (r/MariTide). One felt nothing while her husband, also enrolled, lost his appetite at once, then lost her own food noise by the third shot; her site, she said, had lowered the starting dose and slowed titration (r/Mounjaro).

Beyond the gut, the reports are thin and mostly single. Two long-term posters describe hair thinning, one told by their doctor it was low protein (r/MariTide), one that settled after adding protein (thread). No participant here reports a hospital visit, heart-rate change or mood effect, nor the month-long sickness r/Mounjaro users feared when the phase 2 results first broke (r/Mounjaro). On weight regain, a participant a year in, still blinded, expected to regain everything after the study (r/glp1); replies steered them toward marketed or compounded GLP-1s.

HOW TO READ SELF-REPORTS

The self-reports and the trial agree on the shape of the story: gastrointestinal effects front-loaded into the early doses and fading, as the escalation finding predicts. The anecdotes add texture the abstract does not itemize; they cannot add a rate. Nobody knows how many of these posters got placebo or verified any enrollment, and a few dozen self-selected posts are not the population the trial measured.

When Side Effects Happen — and What Monthly Dosing Changes

No published MariTide data supports a week-by-week side-effect calendar. What the design tells you is where investigators expected trouble: at the dose jumps, which is why the escalation arms exist (PMID 40549887). Monthly dosing changes the shape of that window. A weekly compound’s exposure resets within days; MariTide was built for “markedly prolonged systemic exposure” (PMID 41941715), so the exposure that follows an injection is the exposure for the month. That is a design inference, not a measured result — the abstract doesn’t report when in the cycle GI events occurred or how long they lasted — but it is why the escalation arms were the trial’s most important tolerability question.

Long-Term Safety: What 52 Weeks Can and Can’t Tell You

The published horizon is 52 weeks in 592 people, with “no unexpected safety signals” (PMID 40549887). That is a full year of monthly biologic exposure under observation — and the whole of what has been published. Phase 3 trials were underway when the discovery paper appeared (PMID 41941715). Until they publish, multi-year MariTide safety data doesn’t exist, and anyone describing year three is forecasting. The Nature Reviews Endocrinology item on the phase 1 (PMID 38388678) confirms earlier human data exists but supplies no numbers we can cite.

Who the Trial Enrolled — and Excluded

Trial numbers describe trial populations, and MariTide’s has two. The obesity cohort: 465 participants, 63% female, mean age 47.9, mean BMI 37.9. The obesity-diabetes cohort: 127 participants, 42% female, mean age 55.1, mean BMI 36.5, all with type 2 diabetes (PMID 40549887). The abstract doesn’t list exclusion criteria, so we won’t invent them — but the two cohorts imply that the obesity cohort is the group without diabetes, and the diabetes cohort was smaller, older, and got no escalation arms. Every finding here was generated in screened, monitored people receiving Amgen’s product — a context no research buyer replicates.

Managing and Minimizing Side Effects: What the Trial Did

The trial’s side-effect management was its randomization. Rather than manage GI events after they appeared, the design tested whether a lower starting dose and a gradual climb prevented them, and the abstract’s answer was yes on both counts: GI events were “less frequent with dose escalation and a lower starting dose” (PMID 40549887). No anti-nausea co-medication scheme appears in the abstract, and no dose-reduction protocol is described. We report the escalation finding as what the trial measured, not as a protocol — the arms that escalated did so under clinician management on a pharmaceutical product with known concentration, and the abstract gives no dose steps to copy even if copying were the point.

Dose and Side Effects: What the Design Measured

MariTide’s dose-ranging covered 140, 280, and 420 mg, and the abstract reports efficacy as a range rather than per dose: -12.3% to -16.2% in the obesity cohort, -8.4% to -12.3% in the obesity-diabetes cohort (PMID 40549887). On tolerability the abstract links GI frequency to “a lower starting dose” — so dose mattered — but does not say whether the 140 mg and 280 mg arms had fewer events than 420 mg, or how the every-8-weeks arm compared. The design measured two things a simpler trial wouldn’t — whether a lower starting dose helps (yes) and whether escalation helps (yes) — but not, in the abstract, the trade: how much weight loss, if any, the gentler arms gave up.

DID YOU KNOW

MariTide doses are quoted in hundreds of milligrams — 140, 280, 420 mg — where weekly GLP-1 peptides are quoted in a few milligrams, because most of the molecule is antibody: the GLP-1 peptide rides on an IgG carrier that blocks GIP, and that carrier produces the “markedly prolonged systemic exposure” behind monthly dosing (PMID 41941715). Comparing MariTide milligrams to a weekly peptide’s is comparing a truck’s weight to its cargo’s.

MariTide Alone vs Stacked: What the Data Covers

MariTide is already a two-mechanism molecule, and every finding on this page comes from MariTide alone. No trial has published MariTide in combination with any other compound. That matters more here than for most peptides: the stacks research forums are sketching — MariTide plus an amylin analogue like cagrilintide, or alongside a weekly GLP-1 — would layer a second agent onto an exposure that persists for a month and can’t be walked back. No human safety data exists on any such combination, and the monotherapy abstract can’t be borrowed for it. For the incretin-family sourcing picture, see our GLP-3 guide and retatrutide vendor page.

How MariTide Compares to Retatrutide, Survodutide, and Mazdutide

No head-to-head trial exists, so every comparison is cross-trial — different populations, durations, doses, and reporting conventions. With that flag planted, three differences are structural rather than numerical. First, direction on GIP: MariTide antagonizes the receptor that retatrutide and tirzepatide agonize (PMID 41941715); survodutide and mazdutide skip GIP entirely for glucagon. Second, interval: every other compound in this cluster is weekly; MariTide’s trial ran every 4 weeks and every 8 weeks. Third, reporting: survodutide’s abstract gives GI rates by arm; MariTide’s gives a between-arm comparison and no rates. On efficacy, MariTide’s -12.3% to -16.2% at 52 weeks sits in the band the dual and triple agonists report — see retatrutide side effects and our GLP-1 hub — different trials, different people.

Where the Trial Data Stops: The Research-Vial Reality

Here MariTide is a special case. The trial molecule is an IgG antibody with a GLP-1 peptide conjugated to it, made by biologic manufacturing (PMID 41941715) — not something a peptide synthesizer can make. A storefront selling “MariTide” as a lyophilized peptide is selling something a standard peptide COA (mass spec and HPLC purity on a short chain) cannot confirm, because the trial molecule isn’t a short chain. Whatever is in that vial, the 52-week safety findings above were not generated on it. The usual three gaps apply — identity (a batch-matched COA, read with our lab-testing guide), concentration (reconstitution with bacteriostatic water and our peptide calculator), and no medical monitoring — but for MariTide the first is a chasm. Compounds in this channel are sold strictly for non-human research use.

Sourcing and Verification

MariTide listings are the ones we treat with the most suspicion in the GLP-1 family: antibody-conjugate manufacturing is not what the research-peptide supply chain is built to do. The checklist is the same — batch-matched COA naming the compound and quantity, third-party testing with a verifiable report number — plus one question: does the documentation describe an antibody conjugate, or a peptide? A listing quoting the trial’s 16.2% next to a peptide-style COA has answered it. (Disclosure: some links on this site are affiliate links; they don’t change what we report.) Our vendor directory and Amino Club review show what passing documentation looks like; our guide library covers verification in depth. We do not track MariTide prices and won’t until a research-market product can be verified as the molecule.

US Regulatory Status

MariTide is investigational: not FDA-approved as of this writing, with Amgen running phase 3 trials on the strength of the phase 2 results (PMID 40549887, PMID 41941715). Practically, no prescription version exists, every product in circulation under the name is research-market material sold for non-human research use, and no regulator has evaluated any of it for identity, purity, or safety. When approval status changes, this section changes with it.

PERSONAL OBSERVATION — PI EDITORIAL

In the MariTide listings we’ve reviewed, the pattern is a peptide-vendor product page borrowing an antibody’s clinical trial. The photos show a lyophilized vial; the copy quotes NEJM; the COA, when there is one, describes a molecule that couldn’t have been in the trial. With MariTide the vial may not even be the right kind of object. Until someone publishes third-party characterization of a market product as an antibody conjugate, this page describes Amgen’s molecule and nothing sold under its name.

Frequently Asked Questions

What are the most common MariTide side effects?

Gastrointestinal adverse events. The 592-person phase 2 abstract says they “were common,” were “less frequent with dose escalation and a lower starting dose,” and that “no unexpected safety signals emerged.” It reports no per-event percentages or placebo rate, so no specific nausea or vomiting figure can be cited from it.

Does dose escalation reduce MariTide side effects?

Yes, per the abstract. The obesity cohort reached 420 mg every 4 weeks immediately, after a 4-week escalation, or after a 12-week escalation, and GI adverse events were less frequent with escalation and with a lower starting dose. The abstract does not quantify by how much.

How much weight did people lose on MariTide?

In the obesity cohort, -12.3% to -16.2% at week 52 across MariTide arms versus -2.5% on placebo. In the obesity-diabetes cohort, -8.4% to -12.3% versus -1.7%.

Is MariTide safe?

In the 52-week phase 2, “no unexpected safety signals emerged” among 592 monitored participants. The abstract reports no serious-adverse-event or discontinuation rates, phase 3 results are not yet published, and no safety data exists for research-market products sold under the name.

Why is MariTide dosed monthly, and does that change the side effects?

Because it is a peptide-antibody conjugate: the GLP-1 peptide is attached to an IgG antibody, giving “markedly prolonged systemic exposure.” The phase 2 tested every-4-week and every-8-week dosing. The abstract does not report when in the cycle GI events occurred; the design implication is that exposure after an injection persists for the month.

Is MariTide the same as AMG 133, and can it be bought as a research peptide?

Maridebart cafraglutide, MariTide, and AMG 133 are the same molecule: an antibody conjugate made by biologic manufacturing, not a synthetic peptide, so a vial sold as a lyophilized peptide under the name cannot be verified as the trial molecule by a standard peptide COA. Research-market products are sold strictly for non-human research use.

Glossary of Terms

  • Maridebart cafraglutide: the nonproprietary name for MariTide, Amgen’s once-monthly GLP-1 agonist / GIP antagonist conjugate.
  • AMG 133: Amgen’s development code for the same molecule, used in the phase 1 reports and discovery paper.
  • Peptide-antibody conjugate: a GLP-1 peptide attached to an IgG antibody; the carrier extends exposure enough for monthly dosing and itself blocks the GIP receptor.
  • GIP receptor antagonism: blocking rather than activating the glucose-dependent insulinotropic polypeptide receptor — the opposite direction from tirzepatide and retatrutide.
  • Dose escalation: raising the dose stepwise so tolerance develops; MariTide’s trial randomized 4-week and 12-week escalations against starting at full dose.
  • Treatment policy estimand: an intention-to-treat analysis counting everyone as randomized, including those who stopped — the basis for the trial’s weight-loss figures.
  • COA (certificate of analysis): the lab document identifying a research vial’s contents; batch-matched or it proves nothing — and for an antibody conjugate, a peptide-style COA proves the wrong thing.

References